ReN 1826

Drug Profile

ReN 1826

Latest Information Update: 27 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Bristol
  • Developer ReNeuron
  • Class Anti-inflammatories
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bladder cancer; Prostate cancer

Most Recent Events

  • 27 Jul 2006 Discontinued - Preclinical for Bladder cancer in United Kingdom (unspecified route)
  • 27 Jul 2006 Discontinued - Preclinical for Prostate cancer in United Kingdom (unspecified route)
  • 12 Aug 2003 Enact Pharma has been acquired by, and merged into, Protherics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top